High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

Leukemia Research

Volumn 31, Issue 8, 2007, Pages 1069-1075

  Benson Jr , Don M ^a   Elder, Patrick J ^a   Lin, Thomas S ^a   Blum, William ^a   Penza, Sam ^a   Avalos, Belinda ^a   Copelan, Edward ^a   Farag, Sherif S ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Autologous transplantation; Conditioning regimens; Multiple myeloma

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; AUTOTRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 34249943589     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.08.018     Document Type: Article

References (25)

1. Cunningham D., Paz-Ares L., Milan S., Powles R., Nicolson M., Hickish T., et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12 (1994) 759-763
2. Fermand J., Chevret S., Ravaud P., Divine M., Leblond V., Dreyfus F., et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 82 (1993) 2005-2009
3. Lenhoff S., Hjorth M., Holmberg E., Turesson I., Westin J., Nielsen J.L., et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 95 (2000) 7-11
4. Harousseau J., Attal M., Divine M., Marit G., Leblond V., Stoppa A.M., et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 85 (1995) 3077-3085
5. Lahuerta J., Martinez-Lopez J., Grande C., Blade J., Grande C., Alegre A., et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of the efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 109 (2000) 138-147
6. Blade J., San Miguel J., and Fontanillas M. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 14 (1996) 2167-2173
7. Segeren C., Sonneveld P., ver der Holt B., Vellenga E., Croockewit A.J., Verhoef G.E., et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101 (2003) 2144-2151
8. McElwain T.J., and Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2 (1983) 822-824
9. Barlogie B., Hall R., Zander A., Dicke K., and Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67 (1986) 1298-1301
10. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
11. Imrie K., Esmail R., and Meyer M. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Int Med 136 (2002) 619-629
12. Anagnostopoulos A., Aleman A., Ayers G., Donato M., Champlin R., Weber D., et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100 (2004) 2607-2612
13. Copelan E.A., Penza S.L., Pohlman B., Avalos B.R., Goormastic M., Andresen S.W., et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 25 (2000) 1243-1248
14. Hanel M., Kroger N., Sonnenberg S., Bornhauser M., Kruger W., Kroschinsky F., et al. Busulphan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 81 (2002) 96-102
15. Kroger N., Hoffknecht M., Hanel M., Kruger W., Zeller W., Stockschlader M., et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 21 (1998) 1171-1175
16. Cogle C.R., Moreb J.S., Leather H.L., Finiewitz K., Khan S.A., Reddy V.S., et al. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am J Hematol 73 (2003) 169-175
17. Blade J., Samson D., Reece D., Apperley J., Bjorkstrand B., Gahrton G., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (1998) 1115-1123
18. Kaplan E., and Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 53 (1958) 457-481
19. Durie B., and Salmon S. A clinical staging system for multiple myeloma. Cancer 36 (1975) 842-854
20. Rasmussen T., Bjorkstrand B., Andersen H., Gaarsdal E., and Johnsen H.E. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol 30 (2002) 82-88
21. Lahuerta J., Grande C., Blade J., Martinez-Lopez J., de la Serna J., Alegere A., et al. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk Lymphoma 43 (2002) 67-74
22. Ria R., Falzetti F., Ballanti S., Minelli O., Di Ianni M., Cimminiello M., et al. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematology J 5 (2004) 118-122
23. Powles R., Raje N., Milan S., Millar B., Sheperd V., Mehta J., et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 20 (1997) 435-443
24. Desikan K.R., Tricot G., Dhodapkar M., Fassas A., Siegel D., Vesole D.H., et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 25 (2000) 483-487
25. Bjorkstrand B., Goldstone A.H., Ljungman P., Brandt L., Brunet S., Carlson K., et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma 15 (1994) 265-272